EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Anti‐Modified Protein Antibodies in Rheumatoid Arthritis: Pathogenic, Protective, or Passive Bystander?

Amber-Sarai F L Stalman iD, Diane van der Woude iD

Immunological Reviews · 2026-08 · 341 (1)

DOI: 10.1111/imr.70149 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 28.07.2026. Verfasst von Amber-Sarai F L Stalman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Autoantibodies, Anti-Citrullinated Protein Antibodies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 156 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Research Council, Horizon Europe, Nederlandse Organisatie voor Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The presence of anti‐modified protein antibodies (AMPA) is a hallmark of rheumatoid arthritis (RA). AMPA recognize post‐translationally modified proteins and are cross‐reactive. AMPA include anti‐citrullinated protein antibodies (ACPA), anti‐carbamylated protein antibodies (anti‐CarP), and anti‐acetylated protein antibodies (AAPA). These autoantibodies can be detected years before disease onset and are associated with disease development and progression. Moreover, AMPA have been associated with genetic and environmental risk factors in RA, including human leukocyte antigen (HLA) alleles, smoking, and microbial exposure. Consequently, AMPA have been implicated in RA pathogenesis, yet their exact role remains unclear. ACPA may exert pathogenic, pro‐inflammatory effects through immune complex formation, Fc gamma receptor binding on macrophages, complement activation, and increased neutrophil extracellular trap (NET) formation. Additionally, ACPA have been linked to bone loss and pain induction in mice. However, ACPA may also have protective effects through inhibition of NET release, increased NET clearance, and Fc gamma receptor binding on macrophages. These findings indicate that AMPA may have diverse functions in RA, with both pathogenic and protective effects, whereas some ACPA may not display functional activity. Further studies on AMPA characteristics and mechanisms underlying the pathogenic and protective effects may improve the understanding of the role of AMPA in RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAutoantibodiesAnti-Citrullinated Protein AntibodiesHumansAnimalsProtein Processing, Post-TranslationalAutoantigensReceptors, IgGBystander EffectExtracellular Traps

Stichwörter der Autor:innen

ACPAautoantibodiespathogenesisrheumatoid arthritis

Substanzen

AutoantibodiesAnti-Citrullinated Protein AntibodiesAutoantigensReceptors, IgG

Autor:innen und Institutionen

  • Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.

ORCID-Profile: Amber-Sarai F L Stalman, Diane van der Woude

Förderung

  • Dutch Research Council
  • Horizon Europe
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek
  • HORIZON EUROPE Framework Programme

Zitieren

APA

Stalman, A. F. L., & van der Woude, D. (2026). Anti‐Modified Protein Antibodies in Rheumatoid Arthritis: Pathogenic, Protective, or Passive Bystander?. Immunological Reviews, 341(1). https://doi.org/10.1111/imr.70149

Vancouver

Stalman AFL, van der Woude D. Anti‐Modified Protein Antibodies in Rheumatoid Arthritis: Pathogenic, Protective, or Passive Bystander?. Immunological Reviews. 2026;341(1). doi:10.1111/imr.70149

BibTeX
@article{Stalman2026,
  author = {Stalman, Amber-Sarai F L and van der Woude, Diane},
  title = {Anti‐Modified Protein Antibodies in Rheumatoid Arthritis: Pathogenic, Protective, or Passive Bystander?},
  journal = {Immunological Reviews},
  year = {2026},
  volume = {341},
  number = {1},
  doi = {10.1111/imr.70149}
}
Kostenlos starten →